BACKGROUND We describe the rationale and design for the 'PercutAneous INTervention with biodegradable-polymer based paclitaxel-eluting or sirolimus-eluting versus bare stents for de novo coronary lesions - PAINT trial'. OBJECTIVES To evaluate two novel formulations of paclitaxel-eluting stent and the sirolimus-eluting stent against a stent with the same metallic structure but without polymer ...

AIMS Drug-eluting stents (DES) represent a major advance in interventional cardiology. Along with the success shown, current DES also present limitations related to the presence of polymer-coating, fixed drug, and dose used. With the ISAR (Individualized Drug-Eluting Stent System to Abrogate Restenosis) project, a DES system has been developed that permits individualized choice of the drug and ...

Background—Guidelines recommend that noncardiac surgery be delayed until 30 to 45 days after bare-metal stent implantation and 1 year after drug-eluting stent implantation. Methods and Results—We used linked registry data and population-based administrative health care databases to conduct a cohort study of 8116 patients (Ն40 years of age) who underwent major elective noncardiac surgery in Onta...

Coronary drug-eluting stents are commonplace in clinical practice with acceptable safety and efficacy. Preclinical evaluation of novel drug-eluting stent technologies has great importance for understanding safety and possibly efficacy of these technologies, and well-defined preclinical testing methods clearly benefit multiple communities within the developmental, testing, and clinical evaluatio...

BACKGROUND Guidelines recommend that noncardiac surgery be delayed until 30 to 45 days after bare-metal stent implantation and 1 year after drug-eluting stent implantation. METHODS AND RESULTS We used linked registry data and population-based administrative health care databases to conduct a cohort study of 8116 patients (≥40 years of age) who underwent major elective noncardiac surgery in On...

Two-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Biodegradable or Durable Polymer Recentnetworkmeta-analyseshave raisedconcerns about the safety of biodegradable polymerdrug-eluting stents (BP-DES) compared with durable polymer everolimus-eluting stents (DP-EES).1-3 The NOBORI Biolimus-Eluting vs XIENCE/ PROMUSEverolimus-ElutingStentTrial (NEXT) is a9...

Biodegradable stents are a promising technological development, as they temporarily support the stenotic blood vessel during its healing period, leaving no obstacle for possible future interventions and avoiding long term side effects of conventional drug eluting stents. Moreover, the biodegradable stent material forms an ideal vehicle for local drug delivery [1]. Finite element computer simula...

Coronary artery disease (CAD) is currently a leading cause of death worldwide. Drug-eluting stents (DESs) have been dominant for the treatment of CAD in the interventional cardiology world owing to their efficacy in significantly reducing restenosis. However, late stage stent thrombosis has become a major concern. Stent platform, drug delivery vehicle and type of drug are three parts of DES and...

c s c u r r d t m t p s p a t l t a B b w d a t a 0 d S o s rug-eluting stents have been the most successful strategy or the prevention of restenosis after percutaneous coronary nterventions (1). In line with this, the STRATEGY Single High-Dose Bolus Tirofiban and Sirolimus Eluting tent versus Abciximab and Bare Metal Stent in Acute yocardial Infarction) study showed a marked decrease in he nee...

Animal models of stenting probably predict human responses as the stages of healing are remarkably similar. What is characteristically different is the temporal response to healing, which is substantially prolonged in humans. The prevention of restenosis in recent clinical trials of drug eluting stents may represent a near absent or incomplete phase of intimal healing. Continued long term follo...